Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.
By E. K. Alexander, Giulia C. Kennedy, Z. Baloch, Edmund S. Cibas, Darya I. Chudova, J. Diggans, L. Friedman, R. Kloos, Virginia A. LiVolsi, Susan J. Mandel and 18 more. New England Journal of Medicine, 2012
1,095 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/2a08acd41d4075f412dc5a168effc8473113e518
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Surgery
Citations in the corpus
- Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer (2015, background): “Although a proprietary multigene expression classifier has been validated to corroborate a benign diagnosis in adults with indeterminate nodules (126), there are no studies determining its usefulness in the evaluation of the indeterminate pediatric thyroid nodule.”
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014, background): “Molecular testing of mutation hotspots, rearrangements, and gene expression using fine-needle aspiration specimens has become an effective diagnostic tool to more precisely select patients for thyroid surgery (Alexander et al., 2012; Nikiforov et al., 2011), thereby reducing the number of thyroidect”
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer (2009, positive): “The largest studies of preoperative molecular markers in patients with indeterminate FNA cytology have respectively evaluated a seven-gene panel of genetic mutations and rearrangements (BRAF, RAS, RET/PTC, PAX8/PPARc) (162), a gene expression classifier (167 GEC; mRNA expression of 167 genes) (163),”